Quick Answer
Neurogene Inc. reported Stockholders Equity of $264.89 million for fiscal year 2025.
Neurogene Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $264.89M | -14.7% |
| 2024 | $310.38M | +66.8% |
| 2023 | $186.02M | +227.6% |
| 2022 | -$145.74M | -58.6% |
| 2021 | -$91.88M | -148.0% |
| 2020 | $191.22M | +35.0% |
| 2019 | $141.69M | +95.0% |
| 2018 | $72.67M | -26.5% |
| 2017 | $98.89M | -31.6% |
| 2016 | $144.66M | +33.4% |
| 2015 | $108.42M | +199.9% |
| 2014 | $36.15M | +155.3% |
| 2014 | -$65.39M | +0.5% |
| 2013 | -$65.69M | -28.6% |
| 2012 | -$51.10M | -30.0% |
| 2011 | -$39.31M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $265.54M | +93.2% | -2.8% |
| June 30, 2025 | $273.25M | +76.3% | -6.4% |
| March 31, 2025 | $291.80M | +70.9% | -6.0% |
| December 31, 2024 | $310.38M | +66.8% | +125.9% |
| September 30, 2024 | $137.41M | +175.0% | -11.4% |
| June 30, 2024 | $155.01M | +191.7% | -9.2% |
| March 31, 2024 | $170.78M | +208.4% | -8.2% |
| December 31, 2023 | $186.02M | +227.6% | +201.5% |
- Neurogene Inc. showed a decrease of -14.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, Neurogene Inc.’s stockholders equity has grown by 773.8% (from -$39.31 million to $264.89 million).
- The most recent figure is from Neurogene Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: